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Abstract: In the situation that it would not be able to produce model animals for
mitochondrial diseases caused by mitochondrial DNA (mtDNA) with pathogenic mutations, we
s u c c e e d e di ng e n e r a t i n gm i c ew i t hp a t h o g e n i cd e l e t i o nm u t a n tm t D N A(  mtDNA), named
‘‘mito-mice’’, by direct introduction of mitochondria with  mtDNA into mouse zygotes. In the
mito-mice, accumulation of  mtDNA induced mitochondrial respiration defects in various
tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis,
ischemia, myopathy, heart block, deafness, male infertility, and renal failure. Thus, mito-mice
are the ﬁrst model animal for mtDNA-based diseases, and the mice could be valuable for
understanding precise pathogeneses and testing therapies of mitochondrial diseases. In the
present review, we summarized reverse genetic studies using the mito-mice.
Keywords: mouse model, mitochondrial DNA, large-scale deletion mutation, mitochon-
drial complementation, mitochondrial diseases
Introduction
Mitochondria are one of the organelles, which
can produce 90% or more of all the energy made in
the body by oxidative phosphorylation. Mammalian
mitochondria have multi-copies of own genome (103
and 104 copies/cell), mtDNA, that is replicated and
expressed within the organellar system.1),2) Mam-
malian mtDNA encodes 13 polypeptides which are
essential subunits of complexes I, III, IV, and V for
oxidative phosphorylation on the inner mitochon-
drial membrane and 22 tRNAs and 2 rRNAs which
are necessary for the translation of these 13
polypeptides. The remaining mitochondrial pro-
teins for oxidative phosphorylation, metabolic en-
zymes, DNA and RNA polymerases, and ribosomal
proteins are all encoded by nuclear genome. In
normal individual, nearly all of the mtDNA is
thought to be identical. In some cases, however,
especially in mitochondrial diseases, wild-type and
mutant mtDNAs coexist in cells and organs.
Forward genetic studies,o n eo ft h es t r a t e g i e s
for understanding the genetic reason from pheno-
types of the organism, suggested that accumulation
of pathogenic mtDNAs having large-scale deletion
or point mutation and the resultant mitochondrial
respiratory abnormalities are associated with a
wide variety of disorders, such as mitochondrial
diseases, neurodegenerative diseases, and diabe-
tes.3) Although the pathogenicities of these mtDNA
mutations were proved by co-transmission of the
mutant mtDNAs and respiration defects to human
mtDNA-less cells (rho-0 cells),4)–7) t h e r ei sa sy e tn o
convincing evidence to explain whether accumula-
tion of these pathogenic mutant mtDNAs in tissues
is responsible for the expressions of various clinical
phenotypes.
Reverse genetic studies, one of the strategies
for understanding the mechanism of phenotypic
expression of organisms from genetic manipulation,
could provide model mouse systems for studying
exactly how pathogenic mutant mtDNA is trans-
mitted and distributed in tissues resulting in the
pathogenesis of mitochondrial diseases that show
various clinical phenotypes. However, no proce-
dures are thus far available for introduction of
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No. 5] Proc. Jpn. Acad., Ser. B 84 (2008) 155mutagenized mammalian whole mtDNA into mito-
chondria in living cells or even into isolated
mitochondria. Therefore, generation of mouse mod-
els for mitochondrial diseases so far reported has
been limited by disruption of nuclear DNA-coded
factors related to mitochondrial functions.8)–13)
Adenine nucleotide translocater 1 (Ant1)-deﬁcient
mice were generated by targeted inactivation of the
nuclear-coded Ant1 gene, and showed chronic ATP
deﬁciency, myopathy, and hypertrophic cardiomy-
opathy.8) Mn superoxide dismutase (MnSOD)-deﬁ-
cient mice were generated by inactivating muta-
tions in the nuclear encoded SOD2 gene, and
showed disease phenotypes in skeletal muscle,
heart, liver, and brain.9) Several kinds of mitochon-
drial transcription factor A (Tfam)-deﬁcient mice
were generated by inactivation of the nuclear Tfam
gene.10) Tissue speciﬁc disruption of the Tfam gene
in cardiac muscle cells, pancreatic beta-cells, and
nervous cells induced dilated cardiomyopathy,
diabetes, neurodegenerative diseases, respective-
ly.11)–13)
The eﬀective procedure to generate mouse
models carrying pathogenic mutatnt mtDNA is to
introduce exogenously mitochondria carrying the
mutant mtDNA by microinjection or cell fusion
techniques. Using the cell fusion technique, we have
succeeded in generating mice with mitochondrial
dysfunction by introduction of mitochondria with
somatic mutant mtDNA into mouse zygotes.14)
Generation of mice carrying pathogenic
deletion mutant mtDNA (mito-mice)
In generation of mito-mice,  mtDNA
(Fig. 1A) accumulated in mouse cells was trapped
into mouse rho-0 cells15),16) by isolation of cybrid
cells with various proportions of  mtDNA, and
then respiration-deﬁcient mitochondria were intro-
duced into mouse zygotes using electrofusion with
the enucleated cybrids (Fig. 1B).
Methodologically, there are two essential
points for successful generation of mito-mice. The
ﬁrst point is to isolate mitochondrial donor carrying
mtDNA with somatic mutations from mouse cells.
Since the mutation frequency in mtDNA is about 10
times higher than that in nuclear genome, it has
been known that somatic mutations occur and
accumulate in mtDNA molecules with aging.3)
Thus, we screened the occurrence of somatic
mutations in mtDNA molecules in mouse cells by
trapping the mutant mtDNAs into mouse rho-0 cells
and succeeded in cloning a cybrid cell line carrying
both wild-type mtDNA and  mtDNA.15),16) The
deleted region of  mtDNA is 4,696bp with a
breaking point from nt 7,759–12,454 and includes
6 tRNA genes and 7 structural genes (Fig. 1A). The
mouse  mtDNA is similar to mtDNA with a
common deletion, which have been shown to be
responsible for the pathogenesis of a mitochondrial
encephalomyopathy, Kearns-Sayre syndrome.4),17)
The second point for the successful generation
of mice carrying mutant mtDNA is to introduce
respiration-deﬁcient mitochondria into mouse zy-
gotes (B6 strain) using an electrofusion technique
(Fig. 1B). The respiration-deﬁcient cybrids with
a predominant amount of  mtDNA were used
as mtDNA donors for generation of mice with
 mtDNA. Introduction of  mtDNA into mouse
zygotes was attained by electrofusion of pronucleus
stage embryos with several enucleated cytoplasts of
the cybrids. The embryos fused with cytoplasts
were cultured in vitro for 24–48h, and transferred
to the oviduct of pseudopregnant females. Since F0
progeny was healthy due to low load of  mtDNA
(5.7%–13.0% in tails), we selected F0 females with
 mtDNA as mothers for breeding and obtained
progenies with predominant amounts of  mtDNA,
suggesting the occurrence of  mtDNA transmission
through female germ lines from F0 mothers to
their progeny.
Clinical and pathological features of mito-mice
The great advantages of mito-mice are that
they all share exactly the same nuclear genome
background (B6 strain), and their genetic variation
is restricted to the proportions of the introduced
pathogenic  mtDNA (Fig. 2). Therefore, mito-
mice can provide direct evidence that mitochon-
drial respiration defects induced by the accumula-
tion of  mtDNA are suﬃcient by themselves for
expression of the clinical phenotypes observed in
patients with mutated mtDNA.14),18)
In various tissues of mito-mice with high load
of  mtDNA, approximately more than 75%, mosaic
composition of cells with diﬀerent cytochrome c
oxidase (COX, also known as complex IV) activity
appeared. Since three of the 13 COX subunits
are encoded in mtDNA, it has been well known
that the absence of these subunits or/and tRNAs
due to mtDNA mutations leads to COX deﬁciencies
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Fig. 1. Genetic characterization of  mtDNA molecule and generation of the mito-mice.
A, Gene map of mouse mtDNA. The arc indicates the deleted region (4,696bp) expanded from tRNA
Lys to ND5 genes in
 mtDNA. B, Experimental scheme for producing mice carrying wild-type mtDNA and exogenously introduced  mtDNA. In this
scheme, mitochondria possessing wild-type mtDNA are shown in a block color, and those with  mtDNA in a gray color. Based
on the diﬀerence of COX activity, two mitochondrial populations are classiﬁed in mouse zygotes after electrofusin. One is
COX-positive mitochondria carrying only wild-type mtDNA (black color), which originally exist in mouse zygotes. The other is
COX-negative (respiration-deﬁcient) mitochondria carrying predominant amounts of  mtDNA (gray color), which is introduced
into mouse zygotes from mouse cybrids.
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carrying 88%  mtDNA, for example, we observed
three types of cells, COX-positive, COX-intermedi-
ate, and COX-negative cells.18) Quantitative PCR
analysis demonstrated that the COX activity in
individual cardiac cells we r ec o o r d i n a t e dw i t ht h e
amount of  mtDNA; COX-positive, COX-inter-
mediate, and COX-negative cells carried 76%, 83%,
and 91%  mtDNA, respectively19) (see Fig. 3).
M i t o - m i c ew i t hh i g hl o a do f mtDNA showed
also other mitochondrial disease phenotypes due to
mitochondrial respiration defects, such as low body
weight, lactic acidosis, systemic ischemia, auricu-
loventricular block with Wenckebach periodicity,
hearing loss, renal failures, and male infertili-
ty.14),18),20)–22) Lactic acidosis is one of the typical
clinical phenotypes in patients with mitochondrial
respiration defects, and the symptom suggests
acceleration of glycolytic pathway for producing
ATP without mitochondrial respiration. Early
symptoms of the lactic acidosis, low body weight,
and sperm abnormalities could be detected in
mito-mice carrying approximately more than 75%
 mtDNA.14),22)
 mtDNA load is diﬀerent among the progeny,
and proportion of  mtDNA in cells and tissues
increased with the time14),23) (Fig. 2). In the case of
mito-mice carrying more than 70%  mtDNA at the
birth, they showed mitochondrial respiration de-
fects and disease phenotypes and consequently died
on around 6 months after birth.14),18),20)–22) On the
other hand, mito-mice carrying about 30%–50%
 mtDNA at the birth were healthy, but they
expressed mitochondrial respiration defects and
disease phenotypes and died by around 1.5 years
after birth when  mtDNA load became 75%–
85%.14),18),20)–22) Thus, mitochondrial respiration
defects and the resultant clinical phenotypes were
expressed only when proportion of  mtDNA ex-
ceeded approximately 80%, showing the existence
of threshold eﬀects in pathogeneses of mitochon-
drial diseases (Fig. 3).
Mito-mice carrying a higher amount of
 mtDNA did not express diabetic phenotypes,
and they showed hypoglycemia caused by enhanced
glycolysis.20) This result is unexpected and not
consistent with the conventional hypothesis of
mitochondrial diabetes, which claims that respira-
tion defects caused by mutant mtDNAs in pancre-
atic beta-cells, skeletal muscle and liver tissues are
responsible for their reduced insulin secretion and
resistance of insulin and glucose, respectively,
leading to expression of diabetic phenotypes.3),24)
We cannot yet explain the exact mechanism or
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Fig. 2. Biological features as model systems of mito-mice.
Mito-mice share the same nuclear genome background (B6 strain), and their variations are proportions of pathogenic  mtDNA.
In these mito-mice, mitochondrial respiration defects and the resultant diseases phenotypes were induced only when  mtDNA
accumulated more than 80% in various tissues. Interestingly, healthy mito-mice carrying low load of  mtDNA would show
mitochondrial respiration defects and the resultant diseases phenotypes with aging, because proportion of  mtDNA increases
with the time. As a disadvantage in the use of mito-mice, it is mentioned that to obtain a large population with the same
 mtDNA load is diﬃcult.
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from pancreatic beta-cells carrying predominant
 mtDNA. Possibly the increased level of lactic acid
in mito-mice expressing mitochondrial respiration
defects could enhance insulin secretion, so that
accelerated glucose uptake by respiration-deﬁcient
target tissues, such as muscle tissues, protected
them from progressive glucose deﬁciency. Recently,
it has been reported that protection of diabetic
phenotypes were also obse r v e di nm i c ew i t hm i t o -
chondrial respiration defects induced by muscle
speciﬁc disruption of Tfam gene25) and apoptosis
inducing factor (AIF).26) Thus, the results on mito-
mice,20) together with mice expressing mitochon-
drial respiration defects,25),26) require reassessment
of the conventional concept of mitochondrial
diabetes, which proposes mtDNA mutations as
major pathogenic factors.3),24)
In vivo inter-mitochondrial complementation
Why could mito-mice with low load of
 mtDNA escape mitochondrial respiration defects
and the resultant disease phenotypes? We were able
to answer this question by using an electron micro-
graphic technique that identiﬁes the COX activity
at individual mitochondrial levels.18),19) As shown in
Fig. 1B, it can be considered that mouse zygotes
that were introduced donor mitochondria carrying
 mtDNA possess two mitochondrial populations.
One is COX-positive host mitochondrion carrying
wild-type mtDNA that originally exists in zygotes.
The other is COX-negative donor mitochondrion
carrying  mtDNA that is introduced exogenously.
Considering that individual mitochondria in
living cells undergo constant migration, ﬁssion, and
fusion,27) there is a possibility that mitochondria
could exchange gene products through their fusion
and ﬁssion. In this case, all mitochondria in
single cells of mito-mice would be COX-positive or
COX-negative uniformly (Fig. 4), and exogenous
 mtDNA would be detected even in cells with only
COX-positive mitochondria. If exchange of gene
products did not occur between exogenous donor
COX-negative mitochondria carrying  mtDNA
and COX-positive mitochondria from recipient
zygotes, or even if it occurred, but infrequently
and discontinuously, mitochondria in single cells of
the mito-mice would continue to show mosaic
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Fig. 3. Regulation mechanisms of pathogeneses in mitochondrial diseases due to mutated mtDNA.
A left graph indicates the relationship between  m t D N Al o a da n dC O Xa c t i v i t yi nm i t o - m i c e . Theoretically, it is considered that
load of 50%  mtDNA induces 50% COX activity (blue line in left graph), but there are threshold eﬀects in the relationship (red
line in left graph). That is, all mitochondria in single cells carrying less than 75%  mtDNA show normal mitochondrial
respiration activity, while those carrying more than 80%  mtDNA show respiration defects, due to mitochondrial positive
and negative complementation, respectively. In single cells of the mito-mice, uniform composition of COX-positive, COX-
intermediate, or COX-negative mitochondria is observed (right pictures). Cardiac cells with COX-positive, COX-intermediate,
and COX-negative mitochondria possess 76.3%, 83.2%, and 91.9%  mtDNA, respectively.
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negative mitochondria.
COX electron micrographs of cardiac muscle
tissues from mito-mice clearly showed that all
mitochondria in single cells with low load of
 mtDNA, less than approximately 75%  mtDNA,
were COX-positive (Fig. 3). The appearance of
COX-negative mitochondria was limited to cells
with more than approximately 85%  mtDNA
(Fig. 3). In cells with 75%–85%  mtDNA load,
moreover, COX-intermediate mitochondria were
observed (Fig. 3). The appearance of COX-inter-
mediate mitochondria that possess intermediate
characters of COX-positive and COX-negative mi-
tochondria indicate the exchange of gene products
betweenCOX-positive host mitochondria and COX-
negative donor mitochondria. Importantly, it was
not observed that the coexistence of COX-positive,
COX-intermediate, and COX-negative mitochon-
dria within single cells, irrespective of whether the
tissues contained low or high concentrations of
 mtDNA (Fig. 3). These observations could be
explained by in vivo mitochondrial complementa-
tion between COX-negative donor mitochondria
carrying  mtDNA and COX-positive host mito-
chondria carrying wild-type mtDNA18),19) (Fig. 4).
Since a threshold level of exogenous  mtDNA
required to cause mitochondrial dysfunction in all
mitochondria in single cells that would be more
than approximately 80%, mitochondrial respiratory
function could be maintained quite normally, if
wild-type mtDNA exists more than 20% in single
cells. Although  m t D N Ah a dl o s t6t R N Ag e n e s ,
proteins encoded by  mtDNA could be translated
with the help of the corresponding tRNAs tran-
scribed from wild-type mtDNA. In this case, all
mitochondria in single cells could show normal
mitochondrial respiratory function (mitochondrial
positive complementation) (see Fig. 4).
On the contrary, in somatic cells where the
proportion of wild-type mtDNA is less than 20%,
mitochondrial translation may become limiting due
to the lack of suﬃcient tRNAs transcribed solely
from the wild-type mtDNA. Thus, the translation
phase may be shifted from complementation to
competition of the tRNAs in cells with more than
80%  mtDNA. In this case, progressive inhibition
of overall mitochondrial translation and subsequent
reduction of the mitochondrial respiratory function
would be induced in all mitochondria of single
cells (mitochondrial negative complementation)
(see Fig. 4), leading to the onset of the disease
phenotypes in various tissues.
The occurrence of frequent and continuous
Mitochondrion
with respiration defects
Normal
mitochondrion
Mitochondrial positive complementation A
Mitochondrial negative complementation B
All mitochondria are normalized.
All mitochondria show respiration defects.
Fig. 4. Schematic presentation of mitochondrial complementation.
Individual mitochondria in single cells can exchange genetic contents via fusion and ﬁssion, and they can function as a single
dynamic cellular unit in conforming to ‘‘one for all, all for one’’. There are two types of mitochondrial complementation. One is
mitochondrial positive complementation (A), which occurs when the number of normal mitochondria is more abounding than
that of respiration deﬁcient mitochondria. The other is mitochondrial negative complementation (B) ,w h i c ho c c u r sw h e nt h e
number of respiration-deﬁcient mitochondria is more abounding than that of normal mitochondria. Mitochondrial diseases are
just the latter condition. The mitochondrial positive complementation is mitochondria-speciﬁc system preventing individual from
expression of disease phenotypes by mutated mtDNAs. Black and gray mitochondria indicate normal and respiration-deﬁcient
mitochondria, respectively.
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mice18),19),28) and human cultured cells29) provided
two new concepts on the mitochondrial genetic
system in living animals. One was the loss of the
individuality of each mitochondrion within single
cells. Mammalian cells have been thought to con-
tain hundreds of independent mitochondria, but our
observations gave a totally diﬀerent view that
mitochondria function as a single dynamic cellular
unit. The other important concept was a novel
defense system in mitochondria for avoiding phe-
notypic expression of respiration defects caused
by pathogenic mutant mtDNAs accumulated in
somatic tissues. The mitochondrial theory of
aging proposed that age-associated accumulatzion
of somatic mutations in mtDNAs is responsible
for age-associated mitochondrial dysfunction,30)–33)
since mtDNA is a target of most carcinogens and
mutagens and is continuously exposed to reactive
oxygen species produced in mitochondria. In fact,
accumulation of various kinds of acquired muta-
tions in mtDNAs with age was reported in human
subjects.34)–39) However, this mitochondrial theory
of aging is based on above circumstantial evidence,
and there have been no reports directly proving
that mtDNAs in aged subjects could induce age-
associated mitochondrial defects.40)–43) We found
that extensive and continuous interaction occurred
between mitochondria in various somatic tissues
of mice with  mtDNA, resulting in protection of
mice from expressing severe respiration defects.
Based on these views, we would like to propose
a novel hypothesis on mitochondrial biogenesis,
‘‘interaction theory of mammalian mitochondria’’:
they exchange gene products, and thus lose the
individuality and function as a single dynamic
cellular unit (Fig. 4). This hypothesis has been
conﬁrmed by creation of recombinant mtDNA
molecules in vivo. For examination of in vivo
mtDNA recombination, mito-mouse possessing
 mtDNA of Mus musculus domesticus and wild-
type mtDNA of Mus spretus28) were used. To avoid
PCR jumping artifacts, PCR products were not
used, but whole length mtDNAs puriﬁed from mito-
mouse tissues by EtBr-CsCl centrifugation were
used for cloning and sequence analyses. Of the 318
mtDNA molecules, only three molecules possessed
speciﬁc mutation sites of both M. m. domesticus
and M. spretus mtDNAs.44) Presence of recombi-
nant mtDNA indicates that the exogenous and
endogenous mtDNAs come into close enough prox-
imity to convert their sequences.
New insights for understanding the energy
dependency in biological processes using
mito-mice
Mito-mice can be used as model systems for
understanding in vivo energy-dependent check-
points.21),22) Since most mice with the genetic
disruption of nuclear DNA-encoded proteins func-
tional for mitochondrial biogenesis showed embry-
onic lethal phenotypes,8)–10) it is rather diﬃcult to
examine the signiﬁcance of energy supplied from
mitochondrial respiration in in vivo events, such as
cell diﬀerentiation, maintenance, and regeneration.
On the other hand, mito-mouse embryos with
low load of  mtDNA can escape from the lethal
phenotypes,14),18) because these embryos do not
express mitochondrial respiration defects, due to
mitochondrial positive complementation18) (see
Fig. 4).
Using mito-mice, we have recently succeeded in
showing experimental evidence for mtDNA-based
male infertility, and showing that the mitochondrial
respiration activity is essential for the mammalian
spermatogenesis, especially for progression to
the pachytene stages during meiosis (Fig. 5A and
5B).22) It has been reported that synapsis of
homozygous chromosomes in the mammalian sper-
matogenic meiotic process begins at the zygotene
stage through chromosome movement and attach-
ment45),46) and that several factors for synaptonemal
complexes of homozygous chromosomes, such as
RAD51, DMC1, and cohesin, contain functional
ATP binding domains.47)–49) Actually, abnormal
and incomplete attachment of homozygous chro-
mosomes occurred only in mito-mice with high load
of  mtDNA (Fig. 5C). Our in vivo study using
mito-mice directly demonstrates that there is an
energy-dependent checkpoint in meiotic zygotene
stage during mammalian spermatogenesis, and that
meiotic arrest due to pathogenic mtDNA-derived
mitochondrial respiration defects results in male
infertility. On the basis of these ﬁndings, we have
proposed that some cases of human male infertility
with unknown etiology might result from mitochon-
drial respiratory dysfunction.
Since the  mtDNA load diﬀers in each cell,
spermatogenic cells carrying a relatively lower
proportion of  mtDNA can complete meiosis and
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motility are reduced.22) In comparison with disease
model mice generated by the manipulation of the
nuclear genome, mito-mice are not always suitable
for the drug screening, because it is diﬃcult to
obtain a large population of mito-mice with the
same  mtDNA load. Sperm samples from mito-
mice could be utilized for large-scale screening
drugs designed to restore mitochondrial respiratory
dysfunction, based on the recovery of decreased
sperm motility. Moreover, drugs capable of improv-
ing mitochondrial respiratory dysfunction would
be useful for treating not only mitochondrial
diseases but also male infertility from mitochon-
drial causes.22)
Gene therapy of mito-mice by nuclear
transplantation
Considering the pathogeneses of mitochondrial
diseases regulated by mitochondrial complementa-
tion, dilution of pathogenic mutated mtDNA pop-
ulation is one of the prenatal therapy strategies for
the diseases. Eﬀective procedures to obtain normal
progeny from aﬀected mothers would be either
Mouse-82
A
B6 Mouse-11 Mouse-75 Mouse-85 B
C
Fig. 5. Pathological observations of mito-mouse testes.
A, Schematic presentation of mammalian spermatogenesis. Mammalian spermatogenesis occurs continuously with individual
maturation of sperm and comprises the entire sequence of events by which spermatogonia are transformed into sperm, through
meiotic division of spermatocytes. MCA indicates expression of male meiotic metaphase chromosome-associated acidic protein
(meichroacidin). B, Distribution of spermatogenic cells in the state of meiotic processes. To visualize spermatocytes and
spermatids, testis sections from B6 mouse, Mouse-11, Mouse-75, and Mouse-85 were stained with anti-MCA antiserum, because
anti-MCA is speciﬁc for the cytoplasm of spermatocytes undergoing meiosis and early round spermatids, but not for cytoplasm of
other cells in the testis (see Fig. 5A). Fewer cells stained positive for the anti-MCA decreased in Mouse-75 testis than in Mouse-11
or B6 mouse testes and the number of such cells further decreased in Mouse-85, indicating meiotic abnormalities in
spermatogenesis. The Mouse-11, Mouse-75, and Mouse-85 possessed 11%, 75%, and 85%  mtDNA in their tails. Scale bar, 50mm.
C, Homozygous chromosomes at the zygotene stage in Mouse-82. Abnormal homozygous chromosomes were seen in spermatocyte
nuclei at the zygotene stage (see Fig. 5A). Single and double arrowheads indicate the region with self-attachment and the
degenerated chromosome, respectively. The homozygous chromosomes in a right picture were avoided to form their synapsis due
to the self-attachment. The Mouse-82 possessed 82%  mtDNA in the tail. Scale bar, 2mm.
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enucleated normal zygotes, or cytoplasmic trans-
plantation of mitochondria from normal to mito-
mouse zygotes.50),51) Ooplasmic transfer has been
used as an eﬀective technique to restore normal
developmental potential of oocytes from patients
with embryonic development failure.52),53) However,
the amount of mtDNA copies that could be
introduced into mouse zygotes by cytoplasmic
transplantation is relatively small.
Nuclear transplantation inevitably co-introdu-
ces a small volume of cytoplasm and mitochondria,
but the amount of mtDNA co-introduced with
nucleus is 6% of all mtDNA in zygotes.54) Theoret-
ically, nuclear transplantation would result in
production of nuclear transplanted-zygotes with
6%  mtDNA from mito-mouse zygotes, even when
the mito-mouse zygotes possess 100%  mtDNA.
Since the maximum proportion of  mtDNA in
mito-mouse zygotes was 78%, nuclear transplanta-
tion therapy could hold the proportion of co-trans-
planted  mtDNA at 5% or less. Therefore, nuclear
transplantation was considered to be more eﬀective
than cytoplasmic transplantation for suﬃcient
dilution of  mtDNA in zygotes of mito-mice.
In nuclear transplantation therapy, we ﬁrst
estimated proportions  mtDNA in mito-mouse
zygotes using polar bodies as biopsy samples. Then,
from 39 zygotes possessing 35%  mtDNA, karyo-
plasts were prepared and fused with enucleated
normal zygotes. They were transferred to pseudo-
pregnant females, and the resultant 11 mice at the
weaned stage possessed 11%  mtDNA in their tails.
On the other hand, when 34 mito-mouse zygotes
with 32%  mtDNA were transferred without
nuclear transplantation, obtained 9 mice possessed
66%  mtDNA. They showed mitochondrial respi-
ration deﬁciencies in various tissues and died due to
renal failure at 218–277 days after birth, while
nuclear-transplanted mito-mice showed no abnor-
malities throughout their lives.54)
In human cases, however, there are several
biological problems to be resolved before applying
gene therapy to zygotes. One is that in human cases
maternal transmission of mtDNA with a common
deletion is rare.3) When deletion mutant mtDNA is
transmitted to oocytes,55) the 13 times longer
g e s t a t i o np e r i o di nh u m a n st h a ni nm i c ew o u l d
result in accumulation of a suﬃcient proportion of
deletion mutant mtDNA in nuclear-transplanted
embryos to be lethal before birth. Therefore,
application of nuclear transplantation would be
restricted to patients with mitochondrial diseases,
only when pathogenic mtDNAs in patients were
inherited maternally, and did not possess signiﬁcant
replication advantages over wild-type mtDNA.
For example, zygotes from patients with MELAS
(mitochondrial myopathy, encephalopathy and lac-
tic acidosis, and stroke-like episodes) and MERRF
(myoclonus epilepsy associated with ragged-red
ﬁbers) caused by point mutations in mtDNAs,
respectively, would be appropriate for applying
nuclear transplantation to rescue their progeny.
In these cases, a small proportion of wild-type
mtDNAs was suﬃcient to suppress disease pheno-
types.56),57) The other problem is that nuclear
transplantation results in zygotes possessing the
heteroplasmic state of mtDNA molecules from two
mothers. At the present stage, we could not rule out
the possibility that the heteroplasmic state itself or
the resultant creation of mtDNA recombinants
might induce mitochondrial abnormalities.
Recently, it was reported that the UK Human
Fertilization and Embryology Authority (HFEA)
would allow scientists at the University of New-
castle upon Tyne to transfer the nucleus of a human
fertilized egg into an egg donated by a second
woman. Although the study using mito-mice un-
ambiguously showed that the nuclear transplanta-
tion technique could also be applied to human
patients with mitochondrial diseases as a prenatal
therapy, we would like to stress that we have to
discuss not only biological safety, but also ethical
points in the application of this therapy.
Future works
All genes encoded by human mtDNA are
required for mitochondrial respiratory function,
so that any pathogenic mutations in the mtDNA
could induces mitochondrial respiration defects,
leading to various clinical phenotypes associated
with mitochondrial diseases. Disease phenotypes,
however, are diﬀerent among the types of the
mutation. For example, mutations in tRNA genes
are responsible for MELAS, MERRF, and cardio-
myopathy, whereas ones in structural genes induce
Leigh syndrome and Laber’s disease. Furthermore,
nuclear genome backgrounds could involve in the
diﬀerence of disease phenotypes, since most sub-
units for respiration complexes are encoded in
No. 5] Model mouse for mitochondrial diseases 163nuclear genome. For addressing precise pathogen-
eses in mitochondrial diseases, we have to generate
new mito-mice carrying various mutated mtDNAs
responsible for human cases and various nuclear
genome backgrounds. Recently, we have succeeded
in generating new mito-mou s el i n ec a r r y i n gm t D N A
with a point mutation in COXI gene, and this
mouse have showed lactic acidosis and growth
retardation.58) In addition, we continue to generate
mouse lines with mutated mtDNAs, so we will be
able to report several mouse models for mtDNA-
based diseases in near future.
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